Cargando…

Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide

Hepatitis B virus (HBV) infection is associated with the risk of osteoporosis and bone mineral density (BMD) loss. Tenofovir alafenamide (TAF) is associated with a slightly lower degree of BMD loss compared with tenofovir disoproxil, without loss of the excellent anti-HBV effects. The aim of the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okamura, Takuma, Ichikawa, Tatsuki, Miyaaki, Hisamitsu, Miuma, Satoshi, Motoyoshi, Yasuhide, Yamashima, Mio, Yamamichi, Shinobu, Koike, Makiko, Nakano, Yusuke, Honda, Tetsurou, Yajima, Hiroyuki, Miyazaki, Osamu, Kuribayashi, Yasutaka, Ikeda, Tomonari, Taura, Naota, Nakao, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652643/ https://www.ncbi.nlm.nih.gov/pubmed/34900255 http://dx.doi.org/10.3892/br.2021.1489

Ejemplares similares

Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus
por: Ichikawa, Tatsuki, et al.
Publicado: (2020)

Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease
por: Ichikawa, Tatsuki, et al.
Publicado: (2021)

Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection
por: Ichikawa, Tatsuki, et al.
Publicado: (2019)

Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice
por: Senoo, Takemasa, et al.
Publicado: (2018)

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients
por: Sasaki, Ryu, et al.
Publicado: (2023)

The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease
por: Yamashima, Mio, et al.
Publicado: (2019)

Elevated Fasting Plasma Glucose before Liver Transplantation is Associated with Lower Post-Transplant Survival
por: Katsura, Emi, et al.
Publicado: (2016)

Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis
por: Miuma, Satoshi, et al.
Publicado: (2020)

Two difficulty diagnosis cases of severe veno-occlusive disease
por: Miyaaki, Hisamitsu, et al.
Publicado: (2013)

Hepatitis C Virus Infection Increases c-Jun N-Terminal Kinase (JNK) Phosphorylation and Accentuates Hepatocyte Lipoapoptosis
por: Takaki, Hiroko, et al.
Publicado: (2017)

Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells
por: Miyazoe, Yuri, et al.
Publicado: (2020)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
por: Lin, Hung-Yao, et al.
Publicado: (2022)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study
por: Chen, Yi-Cheng, et al.
Publicado: (2022)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
por: Taura, Naota, et al.
Publicado: (2012)

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
por: Byrne, Ruth, et al.
Publicado: (2018)

An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
por: Charlton, Michael R., et al.
Publicado: (2020)

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B
por: Chen, Ruochan, et al.
Publicado: (2022)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f6puiig2fj1371cf9oshs4d57h